
    
      The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible
      and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody
      therapy

      Secondary, to analyze developments in mutational status as reflected by cfDNA in plasma
      during therapy and at time of progression
    
  